Home -> Law Blog Directory -> Personal Injury Law Blogs -> A Georgia Lawyer
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
Find a Local Lawyer
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Personal Injury Law
: A Georgia LawyerPfizer pulls Mylotarg
The Food and Drug Administration cleared the drug Mylotarg in 2000 under its accelerated approval program, which grants speedy access to drugs that show early promise. The drug was cleared for patients older than 60 with relapsed acute myeloid leukemia, a bone marrow cancer.
A follow-up study was stopped after researchers reported more deaths among patients taking Mylotarg plus chemotherapy, compared with chemotherapy alone. The study was intended to show that adding Mylotarg to chemotherapy increased lifespan, which it failed to do.
Mylotarg carries a warning label about a sometimes fatal liver condition called veno-occlusive disease. The FDA said the rate of reports of the disease associated with the drug increased during its time on the market.
The drug will not be available to new patients, according to the FDA statement.
Pfizer said in a statement that patients currently taking the drug can continue taking it if their doctors approve.
Full post as published by A Georgia Lawyer on June 22, 2010 (boomark / email).
Bextra Product Recall
Find a Bextra Lawyer
Bextra Injury Risks
Bextra Increases Risk of Fatal Heart Attack
Maple Leaf
Pulls Weiners Due to Listeria Concerns
Pfizer, Pharmacia
Found Guilty of Medicaid Fraud
Pfizer
Will Pay $975,000 In Clean Air Settlement

Pfizer Pulls Out of New London
Pfizer Agrees to $894 Million Celebrex and Bextra Settlement
Lawsuit Against Pfizer over Celebrex and Bextra Continues
Pfizer Agrees to First Neurontin Lawsuit Settlement








